Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anja Seckinger

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Oncotarget|October 17, 2015
miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionAnja Seckinger, Tobias Meißner, Jérôme Moreaux, et al.
Oncotarget|February 12, 2015
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myelomaKen Maes, Eva De Smedt, Alboukadel Kassambara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Leukemia|September 9, 2020
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myelomaChunyan Gu, Ting Lu, Wang Wang, et al.
Clinical Epigenetics|October 5, 2018
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsLaurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, et al.
Cell and Tissue Research|March 21, 2007
Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cellsPatrick Wuchter, Judit Boda-Heggemann, Beate K Straub, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Oncotarget|October 17, 2015
miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionAnja Seckinger, Tobias Meißner, Jérôme Moreaux, et al.
Oncotarget|February 12, 2015
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myelomaKen Maes, Eva De Smedt, Alboukadel Kassambara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Leukemia|September 9, 2020
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myelomaChunyan Gu, Ting Lu, Wang Wang, et al.
Clinical Epigenetics|October 5, 2018
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsLaurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, et al.
Cell and Tissue Research|March 21, 2007
Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cellsPatrick Wuchter, Judit Boda-Heggemann, Beate K Straub, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Pageof 13